Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-01

Study Completion Date

2017-07-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This single-arm, open-label study will assess the safety and tolerability of one daily tablet of a commercially available cardiovascular health dietary supplement by questionnaire and blood markers in adults with borderline to mild hypertension over a 6 month period. Although the cardiovascular health dietary supplement being investigated has been on the market for over 20 years, prospective safety data and blood markers of end organ function have not previously been reported.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nutraceutical Supplement in the Management of Hypertension

NCT02663479

Hypertension

COMPLETED PHASE1/PHASE2

To Evaluate the Efficacy of a Nutraceutical in Reducing Cardiovascular Risk in Healthy Subjects

NCT04506749

Cardiovascular Risk

COMPLETED NA

Effects of Dietary Antioxidants on Cardiovascular Risk Factors

NCT00756405

Obesity Hyperlipidemia Hypertension

COMPLETED NA

Double-Blind, Randomized, Cross-Over Trial of Aged Garlic Extract for Hypertension

NCT03211767

Hypertension

COMPLETED NA

Effect of Nitrate-rich Fruit and Vegetable Supplement on Blood Pressure

NCT03486145

High Blood Pressure Flow Mediated Dilation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertension is an important overall risk factor for developing cardiovascular disease in the United States, and is a leading risk factor for cardiovascular events, including myocardial infarction and stroke, and cardiovascular-related mortality with advancing age. Based on population based studies and clinical trials, both systolic blood pressure (SBP) and diastolic blood pressure (DBP) elevations are continuous, strong and independent risk factors for cardiovascular disease.

The product being studies is a cardiovascular health dietary supplement that has been commercially available since 1993. It is currently sold to healthcare practitioners as well as directly to consumers. Some healthcare providers use the product as part of a plan to treat high blood pressure in their patients. This is the first study collecting prospective safety data on this product.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardiovascular Health Dietary Supplement

The cardiovascular health dietary supplement will be administered at a dosage of 1 caplet po per day for a period of 6 months

Group Type EXPERIMENTAL

Cardiovascular health dietary supplement

Intervention Type DIETARY_SUPPLEMENT

Herbal/mineral dietary supplement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiovascular health dietary supplement

Herbal/mineral dietary supplement

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-65
* Systolic blood pressure 120-159 mmHg or diastolic blood pressure 80-99 mmHg upon screening

Exclusion Criteria

* Bradycardia
* Initiation of or changes to blood pressure lowering medications within the last month
* Initiation of or changes to thyroid medications within the last month
* Currently taking any of the following orally (or they were taken within the last month):

* Rauwolfia serpentina, Terminalia arjuna, Tribulus terrestris, Convolvulus pluricaulis, Boerhavia diffusa, Rosa vinca, rose powder, or coral powder
* Beta blockers
* Alpha blockers
* Propranolol
* Digoxin
* Levodopa
* Anti-depressant medications
* Anti-psychotic medications
* Sedatives or tranquilizers
* Present or past history of any of the following:

* Cardiovascular disease
* Heart surgery
* Cardiac arrhythmia
* Abnormal EKG
* Abnormal echocardiogram
* Diabetes
* Chronic liver, kidney or bowel disease
* Ulcers
* Gallbladder disease
* Depression
* Alcoholism
* Obstructive sleep apnea and/or use of a continuous positive airway pressure device
* Parkinson's disease
* Pheochromocytoma
* Cancer within the last 5 years
* Consuming more than fourteen alcoholic beverages per week
* Current smoking/tobacco use
* Current illicit and/or recreational drug use
* Women who are lactating, pregnant or planning pregnancy within the next six months
* Known intolerance or allergy to study agents

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes